Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII

Award Number: R01HL169427
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/15/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII - Title of project: Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII Abstract: Hemophilia A (HA) is an X-linked inherited disease due to mutations in the gene encoding the blood coagulation factor VIII (FVIII), which affects 1 in every 5,000 male births. The majority of HA mutations are nonsense mutations, which introduce premature stop codons leading to no or truncated FVIII protein expression, and missense mutations, which are marked by excessive misfolding and degradation of FVIII protein. Current HA treatments include FVIII concentrate or bispecific monoclonal antibody infusions. However, these treatments are extremely costly and may require frequent office visits. The high cost precludes 80% of the global hemophilia population from routine access to care. Alternative approaches utilizing small molecule drugs offer several advantages, including greatly reduced costs and ease of delivery, which can enhance accessibility and patient compliance. We hypothesize that specific pharmacological molecules can enhance the expression, folding, and trafficking of certain nonsense and missense mutants, leading to increased coagulation factor levels sufficient to restore hemostasis. Gene therapy holds promise for a long-term cure for HA. However, FVIII is intrinsically difficult to express, requiring a high dose of adeno-associated virus (AAV) to produce therapeutic levels of FVIII in HA patients. A high AAV dose can trigger an immune response against the vector, causing complications and limiting FVIII expression. We have identified FVIII variants with 6-fold enhanced expression over the currently used B-domain deleted FVIII. We hypothesize that incorporating these FVIII variants in gene therapy can result in higher plasma FVIII activity levels with lower viral vector doses, offering a superior alternative to the existing FVIII variants. In Aim 1, we recently identified compounds that effectively rescue certain nonsense mutations of FVIII by drug-induced ribosomal readthrough. We will systematically test the most common nonsense FVIII mutations to identify candidate mutations and sequence patterns that will predict candidate mutations for effective readthrough therapy. In Aim 2, after screening compound libraries, we identified proteostasis regulators (PRs) that enhance the secretion of FVIII missense mutants. We will further identify common HA missense mutations that can be rescued by PRs and their molecular mechanism. We will validate in vitro results of both aims in mouse models. Aim 3 will further characterize the high-expression FVIII variants and explore the synergistic effects of combining these variants with existing strategies to boost FVIII expression. The efficacy and safety of candidate variants will be tested in HA mice through AAV-based gene therapy applications. Taken together, these studies will validate the use of small-molecule approaches for HA treatment, tailoring them to each patient's specific mutation profile as effective and convenient treatment options. Our novel high-expression variants will increase plasma FVIII co-factor activity while requiring lower viral vector doses. This advancement is crucial in developing a safer and more effective next-generation HA gene therapy approach.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $492,171 )
2026	2026	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Blood Diseases and Resources Research	000	3	3/19/2026	NON-COMPETING CONTINUATION	$492,171
														Subtotal = $492,171

Issue Date FY: 2025 ( Subtotal = $518,074 )
2025	2025	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Blood Diseases and Resources Research	001	2	8/26/2025	NON-COMPETING CONTINUATION	$51,808
2025	2025	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Blood Diseases and Resources Research	000	2	2/19/2025	NON-COMPETING CONTINUATION	$466,266
														Subtotal = $518,074

Issue Date FY: 2024 ( Subtotal = $518,074 )
2024	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Blood Diseases and Resources Research	001	1	6/7/2024	NEW	$51,807
2024	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Blood Diseases and Resources Research	000	1	3/4/2024	NEW	$466,267
														Subtotal = $518,074

Grand Total All Awards = $1,528,319

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII

Award Number: R01HL169427

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/15/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer